Mainstream

Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data

Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data

Post ContenttrviRead More

You might also be interested in reading Buterin tips distributed validators to simplify Ethereum staking.

August 8, 2025
In Mainstream